Gland Pharma Limited has announced that Chief Executive Officer Shyamakant Giri has resigned effective April 30, 2026. The Board of Directors accepted his resignation following a recommendation from the Nomination and Remuneration Committee, expressing appreciation for his leadership and contributions during his tenure.
Gland Pharma Limited has formally notified the exchanges of a significant leadership change. In a letter dated February 24, 2026, Mr. Shyamakant Giri tendered his resignation as Chief Executive Officer, which the Board accepted on March 3, 2026. His tenure will conclude at the close of business hours on April 30, 2026.
Key Highlights
-
Resignation submitted by Mr. Shyamakant Giri on February 24, 2026
-
Board of Directors accepted the resignation on March 3, 2026
-
Effective date of cessation as CEO and Key Management Personnel: April 30, 2026
-
Board expressed sincere appreciation for his leadership and contributions
-
Mr. Giri assured a smooth transition and thanked the company for its support
This leadership transition marks an important development for Gland Pharma as it prepares for the next phase of its growth journey.
Source: Gland Pharma Limited disclosure to the Stock Exchanges